GT200100119A - Derivados de purina - Google Patents

Derivados de purina

Info

Publication number
GT200100119A
GT200100119A GT200100119A GT200100119A GT200100119A GT 200100119 A GT200100119 A GT 200100119A GT 200100119 A GT200100119 A GT 200100119A GT 200100119 A GT200100119 A GT 200100119A GT 200100119 A GT200100119 A GT 200100119A
Authority
GT
Guatemala
Prior art keywords
compositions
formula
preparation
purina
derivatives
Prior art date
Application number
GT200100119A
Other languages
English (en)
Inventor
Simon John Mantell
Sandra Marina Monaghan
Peter Thomas Stephenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100119A publication Critical patent/GT200100119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTO DE LA FORMULA (I) Y A SUS SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE ESTOS, A PROCEDIMIENTOS PARA LA PREPARACION DE INTERMEDIARIOS UTILIZADOS EN LA PREPARACION DEL COMPUESTO DE LA FORMULA (I), A COMPOSICIONES QUE CONTIENEN DICHOS COMPUESTOS Y A LOS USOS DE DICHOS COMPUESTOS COMO AGONISTAS DE RECEPTOR A2A DE ADENOSINA.
GT200100119A 2000-06-27 2001-06-21 Derivados de purina GT200100119A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives

Publications (1)

Publication Number Publication Date
GT200100119A true GT200100119A (es) 2002-01-31

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100119A GT200100119A (es) 2000-06-27 2001-06-21 Derivados de purina

Country Status (42)

Country Link
EP (1) EP1296996B1 (es)
JP (1) JP2004501929A (es)
KR (1) KR20030036248A (es)
CN (1) CN1432020A (es)
AP (1) AP1372A (es)
AR (1) AR028759A1 (es)
AT (1) ATE267836T1 (es)
AU (1) AU2001264164A1 (es)
BG (1) BG107171A (es)
BR (1) BR0111912A (es)
CA (1) CA2412564C (es)
CZ (1) CZ20023992A3 (es)
DE (1) DE60103537T2 (es)
DK (1) DK1296996T3 (es)
DO (1) DOP2001000195A (es)
EA (1) EA200201291A1 (es)
EC (1) ECSP024396A (es)
EE (1) EE200200712A (es)
ES (1) ES2220775T3 (es)
GB (1) GB0015727D0 (es)
GT (1) GT200100119A (es)
HR (1) HRP20020995A2 (es)
HU (1) HUP0301389A3 (es)
IL (1) IL152529A0 (es)
IS (1) IS6580A (es)
MA (1) MA26918A1 (es)
MX (1) MXPA03000078A (es)
NO (1) NO20025975D0 (es)
NZ (1) NZ521867A (es)
OA (1) OA12294A (es)
PA (1) PA8521001A1 (es)
PE (1) PE20020213A1 (es)
PL (1) PL361384A1 (es)
PT (1) PT1296996E (es)
SI (1) SI1296996T1 (es)
SK (1) SK17332002A3 (es)
SV (1) SV2002000507A (es)
TN (1) TNSN01096A1 (es)
TR (1) TR200401622T4 (es)
UY (1) UY26797A1 (es)
WO (1) WO2002000676A1 (es)
ZA (1) ZA200209557B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272749T3 (es) 2001-08-14 2007-05-01 Eli Lilly And Company Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
AU2005286946B2 (en) * 2004-09-20 2012-03-15 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
KR101677772B1 (ko) 2008-06-11 2016-11-18 레이저젠, 인코퍼레이티드 뉴클레오타이드 및 뉴클레오사이드 그리고 시퀀싱에서의 이들의 이용 방법
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
EP1044004A1 (en) * 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
CA2347512C (en) * 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
EP1296996A1 (en) 2003-04-02
PL361384A1 (en) 2004-10-04
TNSN01096A1 (fr) 2005-11-10
IS6580A (is) 2002-10-10
IL152529A0 (en) 2003-05-29
EP1296996B1 (en) 2004-05-26
CA2412564C (en) 2007-10-02
NZ521867A (en) 2004-04-30
ECSP024396A (es) 2003-02-06
DK1296996T3 (da) 2004-08-16
ES2220775T3 (es) 2004-12-16
NO20025975L (no) 2002-12-12
BG107171A (en) 2003-07-31
SI1296996T1 (en) 2004-10-31
HUP0301389A3 (en) 2005-02-28
EE200200712A (et) 2004-06-15
UY26797A1 (es) 2002-01-31
AP1372A (en) 2005-02-21
EA200201291A1 (ru) 2003-04-24
CN1432020A (zh) 2003-07-23
BR0111912A (pt) 2003-05-13
GB0015727D0 (en) 2000-08-16
MA26918A1 (fr) 2004-12-20
DOP2001000195A (es) 2002-05-15
PE20020213A1 (es) 2002-03-19
WO2002000676A1 (en) 2002-01-03
TR200401622T4 (tr) 2004-08-23
ZA200209557B (en) 2003-12-02
SV2002000507A (es) 2002-07-03
MXPA03000078A (es) 2003-08-19
JP2004501929A (ja) 2004-01-22
DE60103537T2 (de) 2005-07-07
SK17332002A3 (sk) 2004-03-02
HRP20020995A2 (en) 2005-02-28
HUP0301389A2 (hu) 2003-08-28
CZ20023992A3 (cs) 2003-12-17
DE60103537D1 (de) 2004-07-01
KR20030036248A (ko) 2003-05-09
OA12294A (en) 2003-11-14
AR028759A1 (es) 2003-05-21
PT1296996E (pt) 2004-08-31
NO20025975D0 (no) 2002-12-12
AU2001264164A1 (en) 2002-01-08
CA2412564A1 (en) 2002-01-03
PA8521001A1 (es) 2002-04-25
ATE267836T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
GT200100119A (es) Derivados de purina
DOP2001000247A (es) Derivados de purina
HN2000000097A (es) Derivados de purina
UY26397A1 (es) Derivados de la purina
SV2002000199A (es) Derivados de purina ref.pcs10352aajr/bb
PA8511801A1 (es) Derivados de purina
GT200900280A (es) Derivados de 2 piridin carboxamida como moduladores de los canales de sodio
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
CL2011001464A1 (es) Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico.
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
HN1999000196A (es) Derivados de indol
HN2002000348A (es) Combinacion farmaceutica
UY26398A1 (es) Derivados de purina
AR019975A1 (es) Derivados de feniletilamina, procedimiento para su preparacion, preparado farmaceutico que los contiene y su utilizacion
DOP2001000182A (es) 2-aminocarbonil-9h-derivados de purina
HN1999000010A (es) Nuevos derivados del acido dihidroxihexanoico
HN2001000122A (es) Derivados de 2 - aminocarbonil - 9h- purina
HN1999000048A (es) Proceso para la sintesis de los compuestos intermediarios de clorupurina
ECSP003742A (es) Cristales de inhibidor del intercambiador de sodio-hidrogeno tipo i